Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$160.01 USD

160.01
2,428,830

+0.32 (0.20%)

Updated Oct 9, 2024 03:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi

J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

5 Large Drug Stocks to Watch as Sector Picks Up in 2023

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, J&J (JNJ), Novo Nordisk (NVO), AstraZeneca (AZN), Novartis (NVS), and Sanofi (SNY) are worth retaining in your portfolio.

Protagonist (PTGX) Up on Positive Results From FRONTIER Study

Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.

Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?

Style Box ETF report for IWX

Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?

Style Box ETF report for VYM

Zacks Investment Ideas feature highlights: Procter and Gamble, Johnson & Johnson and Abbott Labs

Procter and Gamble, Johnson & Johnson and Abbott Labs have been highlighted in this Investment Ideas article.

Ethan Feller headshot

3 Value Stocks on Sale Now

Growth stocks have clearly led the market thus far in 2023, but will that continue?

Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $155.56, marking a +1% move from the previous day.

Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl

Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult patients.

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Should SPDR Portfolio S&P 500 Value ETF (SPYV) Be on Your Investing Radar?

Style Box ETF report for SPYV

FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus

FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.

Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know

Johnson & Johnson (JNJ) closed the most recent trading day at $153.26, moving -1.52% from the previous trading session.

Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates

Thervance's (TBPH) fourth-quarter loss wider than expected. Revenues decline year over year.

Bayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak

Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.

Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates

Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.

Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Johnson & Johnson (JNJ) Down 6.9% Since Last Earnings Report: Can It Rebound?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Johnson & Johnson (JNJ) Stock Moves -0.14%: What You Should Know

Johnson & Johnson (JNJ) closed the most recent trading day at $157.78, moving -0.14% from the previous trading session.

Halozyme (HALO) Q4 Earnings Top, Revenues Miss, Stock Down

Halozyme Therapeutics (HALO) reports mixed fourth-quarter results. Stock is down in the after-market hours in response to the earnings results.

Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?

Style Box ETF report for PFM

Is ALPS O'Shares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?

Smart Beta ETF report for OUSA

Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up

Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.